Company News
Company News
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent
June 12, 2021
Vancouver, British Columbia, Canada – June 12, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce...
Read more
Company News
CORE ONE LABS INC. ANNOUNCES EXPECTED DELAY AND PROVIDES UPDATE RELATED TO FILING OF ANNUAL REPORT PURSUANT TO NATIONAL POLICY 12-203 – MANAGEMENT CEASE TRADE ORDERS
May 31, 2021
Vancouver, British Columbia, Canada – May 31, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”). ...
Read more
Company News
CORE ONE LABS PROVIDES CLARIFICATION ON TRADING ACTIVITY
May 21, 2021
Vancouver, British Columbia, Canada – May 21, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”). ...
Read more
Company News
CORE ONE LABS INC. PROVIDES UPDATE ON DEFAULT ANNOUNCEMENT PURSUANT TO NATIONAL POLICY 12-203 – MANAGEMENT CEASE TRADE ORDERS
May 13, 2021
Vancouver, British Columbia, Canada – May 13, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”). ...
Read more
Company News
Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease
May 06, 2021
Vancouver, British Columbia, Canada – May 6, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”)...
Read more
Company News
World Renowned Physician Joins Core One Labs as Chief Medical Officer
May 05, 2021
Vancouver, British Columbia, Canada – May 5, 2021 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”)...
Read more